
ESOCAP ANNOUNCES PUBLICATION OF “FUNCTIONALITY AND ACCEPTANCE OF THE ESOCAP SYSTEM - A NOVEL FILM-BASED DRUG DELIVERY TECHNOLOGY: RESULTS OF AN IN VIVO STUDY”



Basel, Switzerland, June 22, 2021

EsoCap has announced that scientists from the University of Greifswald have published exciting data demonstrating the high level of acceptance of its novel drug delivery technology enabling targeted and long-lasting local therapy of the esophagus (Rosenbaum et al., *Pharmaceutics* 2021, 13, 828).

In contrast to tablets, capsules or viscous fluids, which are known for short esophageal transit times, for the first time the EsoCap system ensures a targeted and long-lasting drug delivery in the esophagus. The University of Greifswald team demonstrated, in 12 healthy volunteers, that the EsoCap novel delivery concept, which is based on application of a mucosal adhesive foil, is well accepted and adheres to the esophageal mucosa for at least 15 minutes for maximum treatment efficacy.

“This finding considerably increases the therapeutic options in the field of esophageal diseases,” said Prof. Werner Weitschies, head of the Biopharmaceutics group at the Center of Drug Absorption and Transport. “These results form the basis for a promising new approach, as multiple relevant drug substances, including small molecules and biologics, can be incorporated into the film, making our drug delivery platform applicable to various esophageal diseases.”

“I am greatly impressed by the demonstration of EsoCap technology’s functionality and acceptance,” said Dr. Werner Tschollar, President of the Board of EsoCap. “The EsoCap technology has broad potential in various clinical indications, offering new treatment options for diseases of the esophagus.”

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short contact time of drugs, of one to two seconds, from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing efficient topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocap-biotech.com.

About the University of Greifswald

Across numerous departments and disciplines, the University of Greifswald community advances ideas and innovations that enrich human life. The University’s departments encompass a wide range of fields, including General and Clinical Pharmacology, Biopharmaceutics and Pharmaceutical Technology, Pharmaceutical Biotechnology, and all clinical disciplines. The Center of Drug Absorption and Transport (C_DAT) is an internationally recognized center of expertise, in which research groups from the University of Greifswald and University Medical Center Greifswald investigate the processes of absorption and transport of drugs through to their desired - and unwanted - sites of effect in the human body.



EsoCap

The C_DAT is respected worldwide and is a leading center of excellence for drug absorption and transport in Europe.

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com